Status:
COMPLETED
Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO
Lead Sponsor:
Centro di Riferimento Oncologico - Aviano
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Ovarian cancer (OC) is the leading cause of death from gynecologic cancer. It is estimated that 22,440 new cases of EOC will be diagnosed in 2017 with an estimated 14,080 EOC deaths. Several different...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Diagnosis of a first relapse of high-grade ovarian cancer (≥12 months after the last platinum administration);
- p53 positive tumors evaluated by IHC (\>30% of stained tumor cells);
- Performance Status (Eastern Cooperative Oncology Group scale, ECOG) ≤ 2;- Availability of the tumor sample for immunohistochemical analysis;
- Written informed consent.
Exclusion
- Pre-existing or concurrent tumors, except in situ carcinoma or basophilic carcinoma of the skin;
- Low p53 expression levels (\<30% of stained tumor cells);
- Persistent grade≥ 2 neuropathy;
- Severe heart disease;
- Surgeon's decision of a second curative surgery;
- Uncontrolled active infections;
- Insufficient patient compliance;
- Absence of signed informed consent
Key Trial Info
Start Date :
June 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2022
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT06917469
Start Date
June 20 2018
End Date
June 20 2022
Last Update
April 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro di Riferimento Oncologico - IRCCS
Aviano, Italy